Factors affecting the recovery of hepatic reserve after sustained virologic response by direct‐acting antiviral agents in chronic hepatitis C virus‐infected patients

Since the advent of direct‐acting antiviral (DAA) therapy, the total eradication of hepatitis C virus has been achievable with the recovery of hepatic reserve after achievement of sustained virologic response (SVR). Hence, here, we examined the factors affecting the recovery of hepatic reserve.

[1]  M. Manns,et al.  DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. , 2020, Journal of hepatology.

[2]  M. Nakao,et al.  Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  M. Kurosaki,et al.  Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  Ashish Kumar,et al.  Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. , 2019, Journal of clinical and experimental hepatology.

[5]  Han‐Chieh Lin,et al.  Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score , 2018, PloS one.

[6]  M. Manns,et al.  Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. , 2018, Gastroenterology.

[7]  Siddharth Singh,et al.  Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta‐analysis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  S. Mochida,et al.  Balloon‐occluded retrograde transvenous obliteration as a procedure to improve liver function in patients with decompensated cirrhosis , 2017, JGH open : an open access journal of gastroenterology and hepatology.

[9]  Masahiro Akishita,et al.  Redefining the elderly as aged 75 years and older: Proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society , 2017, Geriatrics & gerontology international.

[10]  H. Toyoda,et al.  Viral eradication reduces all‐cause mortality, including non–liver‐related disease, in patients with progressive hepatitis C virus‐related fibrosis , 2017, Journal of gastroenterology and hepatology.

[11]  Rafael Stern,et al.  Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. , 2016, Journal of hepatology.

[12]  K. Chayama,et al.  Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis , 2015, Hepatology.

[13]  P. Marcellin,et al.  Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis , 2015, Hepatology.

[14]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Chayama,et al.  Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection , 2014, Hepatology.

[16]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[17]  M. Imamura,et al.  Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis , 2013, Journal of Gastroenterology.

[18]  K. Chayama,et al.  Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders , 2012, Hepatology.

[19]  N. Hayashi,et al.  Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C , 2012, Journal of viral hepatitis.

[20]  S. El-Kamary,et al.  All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Y. Imai,et al.  The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan , 2011, Journal of Gastroenterology.

[22]  T. Akita,et al.  Total Numbers of Undiagnosed Carriers of Hepatitis C and B Viruses in Japan Estimated by Age- and Area-Specific Prevalence on the National Scale , 2011, Intervirology.

[23]  R. Marinho,et al.  Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis , 2011, Digestive Diseases and Sciences.

[24]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.

[25]  Yoshiyuki Suzuki,et al.  Efficacy of Interferon Therapy in Elderly Patients with Chronic Hepatitis C , 2006, Intervirology.

[26]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[27]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .